Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 2 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
4 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

Margetuximab shows synergy with pembrolizumab in gastro-oesophageal adenocarcinoma

03 Aug 2020

When combined with the anti-PD-1 checkpoint inhibitor pembrolizumab, the investigational anti-HER2 monoclonal antibody margetuximab demonstrates synergistic antitumour activity against HER2 gastro-oesophageal adenocarcinoma, according to the results of a phase Ib–II trial.

Conducted at centres in the US, Canada, and Asia (Korea, Taiwan, and Singapore), the trial included 95 patients with histologically proven, unresectable, locally advanced or metastatic, HER2-positive, PD-L1-unselected gastro-oesophageal adenocarcinoma. All patients had progressed after at least one previous line of therapy with trastuzumab plus chemotherapy.

In the dose-escalation phase, three patients received infusions of margetuximab 10 mg/kg, while six patients received the recommended dose of 15 mg/kg, in addition to intravenous pembrolizumab 200 mg every 3 weeks. Eighty-six patients were included in the cohort expansion and received the recommended margetuximab dose.

Over a median follow-up of 19.9 months, the combination therapy showed acceptable safety and tolerability; no dose-limiting toxicities were recorded in the dose-escalation phase. The most common grade 3–4 treatment-related adverse events were anaemia (n=4) and infusion-related reactions (n=3).

Nine patients developed serious treatment-related adverse events. There were no reports of treatment-related deaths.

Of the 92 evaluable patients, 17 showed objective response and 49 achieved disease control. The median progression-free survival was 2.73 months, and median overall survival was 12.48 months. The presence of HER2 amplification in ctDNA (n=48) was associated with better response (odds ratio, 7.3, 95 percent confidence interval, 1.5–71.4).

Based on the findings, the combination of margetuximab and pembrolizumab might offer a new chemotherapy-free treatment option for patients with gastro-oesophageal adenocarcinoma, researchers said. A phase II–III MAHOGANY study is underway to investigate the safety and efficacy of margetuximab plus checkpoint inhibitors with or without chemotherapy in the first-line setting.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 2 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
4 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.